Replies to post #457887 on Anavex Life Sciences Corp (AVXL)

[boi568]

I am really getting tired of your bad faith arguments, especially considering you just claimed to have bought more AVXL.

A new statistical analysis by Anavex of the same underlying data does not represent cherry picking the data. And its dosed arm of 338 is significantly greater than a post hoc subset of 90.

Furthermore, in light of the emerging FDA approach to early AD trials, Anavex is simply using the ADAS-Cog endpoint as its sole basis for seeking FDA approval. This puts the company in an excellent position to file an NDA to go along with its regulatory progress with the EU, since the gatekeeping p value reverts to .05, which has been easily met by the 2b/3 AD cognitive p value of .0226.

And the reason I accuse you of bad faith is I know you understand all this, yet continue to post your BS.